EUVIMEDEUVIMED entdecken
Crossref

Breviscapine targets EGFR and SRC to abrogate diabetes-driven GPX4 lactylation and ferroptosis resistance in gastric cancer

Hong Mei Hu, Jia Le Deng, Yan Pan, Zi Han Wang, Jing Zhang, Xin Yu Gu, Sheng Xian Fan, Ji Zhong Zhao

Phytomedicine · 2025-11 · 148 · 157387

DOI: 10.1016/j.phymed.2025.157387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025-11. Verfasst von Hong Mei Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Cell Biology, School of Life Sciences, Jiangsu Normal University, Xuzhou, Jiangsu 221116, PR China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Ferroptosis, Phospholipid Hydroperoxide Glutathione Peroxidase, Flavonoids. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Jiangsu Province Department of Education, Nanjing University, Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mounting evidence identifies cancer as the leading cause of death in diabetic patients, necessitating therapies that disrupt this pathological nexus. We demonstrate that the flavonoid breviscapine inhibits diabetes-accelerated gastric cancer through a novel 'contextual programmed lethality' mechanism targeting the lactylation-ferroptosis axis. Employing network pharmacology, molecular dynamics simulations, and in vitro experiments, we revealed EGFR and SRC as core breviscapine targets within AGEs-RAGE-glycolytic networks, with molecular dynamics confirming stable high-affinity binding (ΔG 24 h), conferring ferroptosis resistance. Breviscapine reverses this by: 1) dismantling lactylation-dependent GPX4 stabilization (half-life reduced to 5.1 ± 0.4 h), and 2) co-opting restored cholesterol synthesis (+2.3-fold) to fuel lethal lipid peroxidation (LPO increased 3.2-fold). This dual action selectively suppressed AGEs-driven malignancy-reducing proliferation by 63 ± 5.2 % and migration by 58 ± 4.3 %-while reversing Warburg metabolism (lactate decreased to 82 ± 7 % baseline). Efficacy was abrogated by LDHA overexpression or HMGCR inhibition, confirming mechanistic specificity. By exploiting metabolic rewiring to induce iron-dependent death exclusively in diabetic microenvironments, breviscapine emerges as a novel therapeutic strategy against diabetes-aggravated cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsFerroptosisPhospholipid Hydroperoxide Glutathione PeroxidaseFlavonoidssrc-Family KinasesHumansErbB ReceptorsCell Line, TumorAnimalsMiceMolecular Dynamics SimulationLipid Peroxidation

Stichwörter der Autor:innen

BreviscapineEGFRFerroptosisGastric cancerLactylationSRC

Substanzen

Phospholipid Hydroperoxide Glutathione PeroxidaseFlavonoidsErbB Receptorssrc-Family KinasesEGFR protein, human

Autor:innen und Institutionen

  • Lab of Cell Biology, School of Life Sciences, Jiangsu Normal University, Xuzhou, Jiangsu 221116, PR China.
  • Department of Colorectal Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China. Electronic address: fanshengxian66@126.com.
  • Lab of Cell Biology, School of Life Sciences, Jiangsu Normal University, Xuzhou, Jiangsu 221116, PR China. Electronic address: jz_zhao@jsnu.edu.cn.

Förderung

  • Jiangsu Province Department of Education
  • Nanjing University
  • Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital
  • National Natural Science Foundation of China

Zitieren

APA

Hu, H. M., Deng, J. L., Pan, Y., Wang, Z. H., Zhang, J., Yu Gu, X., Fan, S. X., & Zhao, J. Z. (2025). Breviscapine targets EGFR and SRC to abrogate diabetes-driven GPX4 lactylation and ferroptosis resistance in gastric cancer. Phytomedicine, 148, 157387. https://doi.org/10.1016/j.phymed.2025.157387

Vancouver

Hu HM, Deng JL, Pan Y, Wang ZH, Zhang J, Yu Gu X, et al. Breviscapine targets EGFR and SRC to abrogate diabetes-driven GPX4 lactylation and ferroptosis resistance in gastric cancer. Phytomedicine. 2025;148:157387. doi:10.1016/j.phymed.2025.157387

BibTeX
@article{Hu2025,
  author = {Hu, Hong Mei and Deng, Jia Le and Pan, Yan and Wang, Zi Han and Zhang, Jing and Yu Gu, Xin and Fan, Sheng Xian and Zhao, Ji Zhong},
  title = {Breviscapine targets EGFR and SRC to abrogate diabetes-driven GPX4 lactylation and ferroptosis resistance in gastric cancer},
  journal = {Phytomedicine},
  year = {2025},
  volume = {148},
  pages = {157387},
  doi = {10.1016/j.phymed.2025.157387}
}
Kostenlos starten →